Do analysts recommend INM or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer APM or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher earnings and valuation, APM or ABP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group N/A N/A -$1.36M N/A N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is APM or ABP more profitable?

Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Abpro N/A N/A -344.76%

Do analysts rate ABP or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ABP or CDT?

Abpro is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is ABP or CDT more profitable?

Abpro's return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% CDT Equity N/A -4,263.33% -529.91%

Do analysts rate ABP or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABP or BGMS more profitable?

Abpro's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts recommend ABP or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ABP or RDHL?

Redhill Biopharma has higher revenue and earnings than Abpro. Abpro is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Redhill Biopharma $290K 18.25 -$430K $1.05 thousand 0.00

Is ABP or RDHL more profitable?

Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Redhill Biopharma N/A N/A N/A

Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 06/5/2026

Compare

ABP vs. INM, APM, CDT, BGMS, and RDHL

Should you buy Abpro stock or one of its competitors? MarketBeat compares Abpro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abpro include InMed Pharmaceuticals (INM), Aptorum Group (APM), CDT Equity (CDT), Cyclacel Pharmaceuticals (BGMS), and Redhill Biopharma (RDHL). These companies are all part of the "pharmaceutical products" industry.

How does Abpro compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, InMed Pharmaceuticals' average media sentiment score of 0.00 equaled Abpro'saverage media sentiment score.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Abpro	Neutral

Abpro has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Abpro's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Abpro	N/A	N/A	-344.76%

Abpro has lower revenue, but higher earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.03	-$8.16M	-$2.89	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Abpro beats InMed Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Abpro compare to Aptorum Group?

Aptorum Group (NASDAQ:APM) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Aptorum Group's average media sentiment score of 0.00 equaled Abpro'saverage media sentiment score.

Company	Overall Sentiment
Aptorum Group	Neutral
Abpro	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Abpro	N/A	N/A	-344.76%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Aptorum Group beats Abpro on 3 of the 5 factors compared between the two stocks.

How does Abpro compare to CDT Equity?

Abpro (NASDAQ:ABP) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Abpro is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

23.3% of Abpro shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, CDT Equity had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for CDT Equity and 0 mentions for Abpro. CDT Equity's average media sentiment score of 0.67 beat Abpro's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
CDT Equity	Positive

Abpro's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
CDT Equity	N/A	-4,263.33%	-529.91%

Summary

Abpro beats CDT Equity on 7 of the 10 factors compared between the two stocks.

How does Abpro compare to Cyclacel Pharmaceuticals?

Abpro (NASDAQ:ABP) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Abpro's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Cyclacel Pharmaceuticals has higher revenue and earnings than Abpro. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Cyclacel Pharmaceuticals	$1.53M	3.98	-$3M	-$4.54	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

23.3% of Abpro shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cyclacel Pharmaceuticals had 5 more articles in the media than Abpro. MarketBeat recorded 5 mentions for Cyclacel Pharmaceuticals and 0 mentions for Abpro. Cyclacel Pharmaceuticals' average media sentiment score of 0.20 beat Abpro's score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Cyclacel Pharmaceuticals	Neutral

Summary

Cyclacel Pharmaceuticals beats Abpro on 7 of the 11 factors compared between the two stocks.

How does Abpro compare to Redhill Biopharma?

Abpro (NASDAQ:ABP) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

In the previous week, Redhill Biopharma had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Redhill Biopharma and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Redhill Biopharma	Neutral

23.3% of Abpro shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Redhill Biopharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher revenue and earnings than Abpro. Abpro is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Redhill Biopharma	$290K	18.25	-$430K	$1.05 thousand	0.00

Summary

Redhill Biopharma beats Abpro on 6 of the 9 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-0.12	18.93	23.75	23.75
Price / Sales	N/A	176.22	479.79	84.65
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	-0.06	8.04	10.28	6.78
Net Income	-$7.23M	$23.89M	$3.57B	$337.51M
7 Day Performance	N/A	-6.04%	-1.45%	-2.72%
1 Month Performance	N/A	2.72%	3.25%	1.87%
1 Year Performance	-91.73%	36.16%	23.34%	26.60%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
INM InMed Pharmaceuticals	1.3892 of 5 stars	$1.66 -3.5%	N/A	-44.9%	$5.50M	$4.94M	N/A	10	Gap Down
APM Aptorum Group	0.8147 of 5 stars	$0.85 +0.7%	N/A	-5.6%	$5.40M	N/A	N/A	30
CDT CDT Equity	0.4259 of 5 stars	$1.10 +24.4%	N/A	-99.9%	$5.35M	N/A	N/A	3	Gap Up High Trading Volume
BGMS Cyclacel Pharmaceuticals	1.3593 of 5 stars	$0.96 -0.5%	N/A	N/A	$5.30M	$1.53M	N/A	14	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. INM, APM, CDT, BGMS, and RDHL

How does Abpro compare to InMed Pharmaceuticals?

Summary

How does Abpro compare to Aptorum Group?

Summary

How does Abpro compare to CDT Equity?

Summary

How does Abpro compare to Cyclacel Pharmaceuticals?

Summary

How does Abpro compare to Redhill Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. INM, APM, CDT, BGMS, and RDHL

How does Abpro compare to InMed Pharmaceuticals?

Do insiders and institutionals believe in INM or ABP?

Does the media prefer INM or ABP?

Is INM or ABP more profitable?

Which has stronger earnings & valuation, INM or ABP?

Do analysts recommend INM or ABP?

Summary

How does Abpro compare to Aptorum Group?

Do institutionals and insiders believe in APM or ABP?

Does the media refer more to APM or ABP?

Is APM or ABP more profitable?

Which has higher earnings and valuation, APM or ABP?

Do analysts prefer APM or ABP?

Summary

How does Abpro compare to CDT Equity?

Which has higher valuation and earnings, ABP or CDT?

Do insiders & institutionals have more ownership in ABP or CDT?

Do analysts rate ABP or CDT?

Does the media favor ABP or CDT?

Is ABP or CDT more profitable?

Summary

How does Abpro compare to Cyclacel Pharmaceuticals?

Is ABP or BGMS more profitable?

Which has preferable earnings & valuation, ABP or BGMS?

Do analysts rate ABP or BGMS?

Do institutionals and insiders have more ownership in ABP or BGMS?

Does the media favor ABP or BGMS?

Summary

How does Abpro compare to Redhill Biopharma?

Does the media refer more to ABP or RDHL?

Do institutionals & insiders hold more shares of ABP or RDHL?

Is ABP or RDHL more profitable?

Do analysts recommend ABP or RDHL?

Which has stronger earnings & valuation, ABP or RDHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools